- Home
- CRVS vs MMD Comparison
CRVS vs MMD Comparison
Compare CRVS & MMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- MMD
- Stock Information
- Founded
- CRVS 2014
- MMD 2012
- Country
- CRVS United States
- MMD United States
- Employees
- CRVS N/A
- MMD N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- MMD Investment Managers
- Sector
- CRVS Health Care
- MMD Finance
- Exchange
- CRVS Nasdaq
- MMD Nasdaq
- Market Cap
- CRVS 516.0M
- MMD 439.8M
- IPO Year
- CRVS 2016
- MMD N/A
- Fundamental
- Price
- CRVS $4.99
- MMD $14.85
- Analyst Decision
- CRVS Buy
- MMD
- Analyst Count
- CRVS 4
- MMD 0
- Target Price
- CRVS $12.83
- MMD N/A
- AVG Volume (30 Days)
- CRVS 1.6M
- MMD 74.7K
- Earning Date
- CRVS 11-12-2024
- MMD 01-01-0001
- Dividend Yield
- CRVS N/A
- MMD 4.88%
- EPS Growth
- CRVS N/A
- MMD N/A
- EPS
- CRVS N/A
- MMD N/A
- Revenue
- CRVS N/A
- MMD N/A
- Revenue This Year
- CRVS N/A
- MMD N/A
- Revenue Next Year
- CRVS N/A
- MMD N/A
- P/E Ratio
- CRVS N/A
- MMD N/A
- Revenue Growth
- CRVS N/A
- MMD N/A
- 52 Week Low
- CRVS $1.30
- MMD $14.30
- 52 Week High
- CRVS $10.00
- MMD $17.67
- Technical
- Relative Strength Index (RSI)
- CRVS 28.00
- MMD 23.02
- Support Level
- CRVS $3.77
- MMD $15.60
- Resistance Level
- CRVS $7.44
- MMD $15.46
- Average True Range (ATR)
- CRVS 0.60
- MMD 0.27
- MACD
- CRVS -0.41
- MMD -0.08
- Stochastic Oscillator
- CRVS 25.85
- MMD 1.37
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
MainStay MacKay DefinedTerm Municipal Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company may also invest in TOB (Tender Option Bonds) Floaters and TOB Residuals issued by the TOB Issuer. It evaluates its performance against Barclays Municipal Bond Index.